Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zecuity Redesign Got Migraine Patch Through FDA, But Burning Continued

Executive Summary

FDA worries about burning and scarring with the battery-powered Zecuity patch prompted NuPathe to reconfigure the drug-device combo; our Drug Review Profile shows how FDA thought the problem was solved, but adverse reaction reports soon after launch led to marketing suspension.

Advertisement

Related Content

Drug Review Profiles: Behind The Scenes At US FDA
US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews
Teva Zecuity's Safety: Burns Go From Non-Issue In Label To Product Puller
Teva Wins Bidding For NuPathe And Its Migraine Patch, Topping Endo
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
NuPathe Must Patch Together New Zelrix Launch Timetable After "Complete Response" Letter

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel